spacer
home > ict > spring 2019 > receptivity, recruitment, and retention
PUBLICATIONS
International Clinical Trials

Receptivity, Recruitment, and Retention

The struggle to identify qualified patients for clinical trials continues to be an industry challenge. Competing and complex protocols, stringent regulatory requirements, strict inclusion/exclusion criteria, high costs, and a deficit in provider recommendations means that 46% of clinical trials experience delays due to issues with patient enrolment. Keeping patients engaged in the clinical trial and maintaining retention rates is equally challenging. Companies strategise numerous initiatives to ensure that successful patient recruitment and retention plans are in place with the research site while understanding and meeting patients’ needs across diverse strata. With the surge of technology and personalised services, combined with traditional and digital marketing outreach efforts, the industry may start to witness a more positive outcome in addressing patient recruitment and retention challenges.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As President of ClinEdge and co-founder of ClinX, Christian Burns oversees day-today operations, project-manages clients, and executes tasks at many levels for the divisions of ClinX. He is passionate about serving patients and sites by identifying innovative solutions to transform the traditional clinical model. He holds a BS in Public Health, Kineisology, and Allied Health from the University of Tampa. ClinX is the parent company of ClinEdge, BTC Network, and GuideStar Research.

Joan Chambers is the Vice President of Marketing and Strategy at ClinX. With over 20 years’ experience in the health life sciences, she is responsible for planning and managing the marketing strategy for the divisions of ClinX. Joan is recognised for building profitable divisions, growing business lines, streamlining operations, and assessing critical business challenges to provide solutions and drive organisational success in the marketplace. Joan is the former Chief Operating Officer of CenterWatch, and she holds a BSc in Marketing from Central Connecticut State University, US.

As Marketing Content Specialist at ClinX, Melissa Daley develops social media and marketing content strategies and produces a variety of collateral with creative, effective messaging. Melissa has served as an educator in higher education for close to two decades. She holds a BA in English and communication arts from Emmanuel College, Boston, US, and a MA in visual media arts from Emerson College, Boston, US.
spacer
Christian Burns
spacer
spacer
spacer
Joan Chambers
spacer
spacer
spacer
Melissa Daley
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Presspart Manufacturing Ltd

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement